๋ฐํ๋ก์ฌ๋ฏผ ๋ฉ์ค์ฐ์ผ
**๋ฐํ๋ก์ฌ๋ฏผ ๋ฉ์ค์ฐ์ผ(Deferoxamine mesylate)**์ ์์ํ์์ ์ฃผ๋ก ๊ธ์ฑ ์ฒ ์ค๋ (์: ์ฒ ๋ถ ๋ณด์ถฉ์ ๋๋ ์ฐ์ ํก์์ ์ญ์ทจ)์ ๊ตฌ๋ช ํด๋ ์ ๋ก ์ฌ์ฉ๋๋ ๋งค์ฐ ํน์ด์ ์ธ **์ฒ ํฌ๋ ์ดํธ์ **์ ๋๋ค. ์๋ฃจ๋ฏธ๋ ์ค๋ ๋ฐ ๊ธ์ฑ ์ฌ๊ทผ ํํ์ ๋ณด์กฐ ์น๋ฃ์ ๋ก๋ ๊ฐํน ํ๊ฐ๋์ง๋ง, ์ฌ๊ด๋ฅ ์์์ ๋ํ ํจ๋ฅ์ ์ค๋ง์ค๋ฌ์ด ํธ์ ๋๋ค. ์ฃผ์ ์์ ํฌ์ธํธ: * **๋์ ์นํ๋ ฅ**: ํ๋ฅ ๋ฐ ์กฐ์ง์ ์ ๋ฆฌ ์ฒ ์ ํน์ด์ ์ผ๋ก ํ์ ํํ๊ณ ๊ฒฐํฉํ์ฌ ์ฒ ๋ก ์ธํ ์ฐํ ์์์ ๋ฐฉ์งํฉ๋๋ค. * **์๋ณ ๋ณ์**: ์ฑ๊ณต์ ์ธ ํฌ๋ ์ดํธํ์ ํน์ง์ ์ฐ์ด ํํฌ์ ๋๋ '๋ก์ ์์ธ(vin rosรฉ)' ์์ ์๋ณ์ด ์์ฑ๋๋ ๊ฒ์ด๋ฉฐ, ์ด๋ ์ฒ -ํฌ๋ ์ดํธ ๋ณตํฉ์ฒด๊ฐ ๋ฐฐ์ค๋๊ณ ์์์ ๋ํ๋ ๋๋ค. * **ํฌ์ฌ**: ๋ฐ๋์ ๋น๊ฒฝ๊ตฌ(์ผ๋ฐ์ ์ผ๋ก IM ๋๋ ๋๋ฆฐ IV ์ง์ ์ ์ )๋ก ํฌ์ฌํด์ผ ํฉ๋๋ค. ๊ฒฝ๊ตฌ ํฌ์ฌ๋ ์์ฅ๊ด์ ์ฒ ๋ถ ํก์๋ฅผ ์ญ์ค์ ์ผ๋ก ์ฆ๊ฐ์ํฌ ์ ์์ผ๋ฏ๋ก ์ผ๋ฐ์ ์ผ๋ก ๊ธ๊ธฐ์ ๋๋ค.
์์ฉ ๊ธฐ์ : Deferoxamine acts by directly binding to free iron to neutralize its toxicity: * The drug possesses three hydroxamic groups that have a high affinity for **ferric (Feยณโบ) ions**. * Deferoxamine + Feยณโบ โ **Ferrioxamine** (a stable, water-soluble chelate complex). * By sequestering the iron, it prevents the metal from participating in the **Fenton reaction**, thereby halting the production of damaging reactive oxygen species (hydroxyl radicals). * The ferrioxamine complex is then readily excreted by the kidneys into the urine. It does not significantly chelate other essential trace metals or electrolytes (except aluminum).
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Severe iron toxicosis ยท 40 mg/kg IM q4-8 hours ยท IM ยท q4-8h ยท Until urine clears or serum iron levels return to normal ยท Cat dosages are not well established; extrapolated from general animal doses.
- Severe iron toxicosis ยท 15 mg/kg/hour ยท IV ยท CRI ยท 2-3 days ยท Cat dosages are not well established; extrapolated from general animal doses.
- Severe iron toxicosis ยท 10 mg/kg IM or IV q8h for 24 hours ยท IM/IV ยท q8h ยท 24 hours ยท Cat dosages are not well established.
- Severe iron toxicosis ยท 40 mg/kg IM q4-8 hours ยท IM ยท q4-8h ยท Until urine clears or serum iron levels return to normal ยท Most effective within the first 24 hours. IM route is preferred as too rapid IV administration can cause hypotension and pulmonary edema.
- Severe iron toxicosis ยท 15 mg/kg/hour ยท IV ยท CRI ยท 2-3 days (until serum iron < 300 microliters/dL or below TIBC) ยท Initiate ASAP or at least within 12 hours of ingestion. Give as a constant rate infusion. If CRI not possible, give 40 mg/kg IM q4-8h.
- Severe iron toxicosis ยท 10 mg/kg IM or IV q8h for 24 hours ยท IM/IV ยท q8h ยท 24 hours
- Ferric ion chelator during treatment of cardiac arrest (experimental) ยท 5-15 mg/kg IV , IM or SC ยท IV/IM/SC ยท Single dose or as directed
- Ferric ion chelator during treatment of cardiac arrest (experimental) ยท 10 mg/kg IV , IM q2h twice, then three times daily for 24 hours ยท IV/IM ยท q2h twice, then TID ยท 24 hours
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Severe renal failure (unless dialysis is used to remove the ferrioxamine complex)
์ด์๋ฐ์
- Allergic reactions (hives, wheezing)
- Auditory neurotoxicity (with chronic, high-dose therapy)
- Pain or swelling at injection sites
- Gastrointestinal distress
- Hypotension, tachycardia, and convulsions (if given IV too rapidly)
- Pulmonary edema (associated with rapid IV administration)
์ฝ๋ฌผ ์ํธ์์ฉ
- Prochlorperazine ยท Concurrent use may cause temporary impairment of consciousness.
- Vitamin C (Ascorbic Acid) ยท May be synergistic in removing iron, but could lead to increased tissue iron toxicity, especially in cardiac muscle. Use with extreme caution in patients with preexisting cardiac disease.
๋ชจ๋ํฐ๋ง
- Serum iron levels
- Total iron-binding capacity (TIBC)
- Serum ferritin
- Urine color (monitor for clearing of the 'vin rosรฉ' color)
- Blood pressure and heart rate (especially during IV infusion)
- Ophthalmic examinations (if used chronically)
๊ณผ์ฉ๋
Acute overdosage or excessively rapid IV administration can lead to severe hypotension, tachycardia, convulsions, hives, wheezing, and pulmonary edema. Chronic high-dose use may lead to hypocalcemia, thrombocytopenia, and auditory/visual neurotoxicity. Treatment is supportive and symptomatic.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.